3rd generation glp 1 agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports GLP-1 Agonists Market Report 2025-2033,

Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats

Lenroot RK, Gogtay N, Greenstein DK, Wells EM, Wallace GL, Clasen LS, et al

Most available data comes from early-stage or limited clinical studies, which describe how these peptides affect biological pathways rather than long-term outcomes

BPC-157 before or after PRP for rotator cuff tear The timing of peptide administration relative to regenerative treatments like Platelet-Rich Plasma (PRP) is a critical consideration

In silico profiling has demonstrated that the severity of diabetic tubulointerstitial injury correlates significantly with the dysregulation of CASP1 and LYZ, both of which represent pivotal hub genes orchestrating NET formation and clearance (221)